Ruderman Stephanie A, Nance Robin M, Crane Heidi M, Cachay Edward, Kitahata Mari M, Napravnik Sonia, Whitney Bridget M, Heckbert Susan R, Attia Engi F, Longenecker Chris T, Hoffmann Alexander P, Budoff Matthew J, Ma Jimmy, Christopoulos Katerina, Hunt Peter W, Moore Richard D, Keruly Jeanne C, Burkholder Greer, Bamford Laura, Willig Amanda L, Chander Geetanjali, Saag Michael S, Drumright Lydia N, Feinstein Matthew J, Crothers Kristina, Delaney Joseph A C
University of Washington, Seattle, Washington.
University of California, San Diego, San Diego, California.
AIDS. 2025 Apr 1;39(5):579-583. doi: 10.1097/QAD.0000000000004095. Epub 2024 Dec 17.
People with HIV (PWH) have benefited greatly from antiretroviral therapy, but face additional challenges from age-related comorbid conditions, particularly cardiovascular disease including venous thromboembolism (VTE). Little is known about the effect of HIV viremia and immunodeficiency on VTE risk in this population.
We assessed incident, centrally adjudicated VTE among 21 507 PWH in care between January 2009 and December 2019 within the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort. We examined the association of three measures of HIV viral load (baseline, current, cumulative) and current CD4 + cell count with VTE. Cumulative viral load (copy-days of viremia) was estimated with a time-weighted sum using the trapezoidal rule. We modeled the association between viral load and VTE using Cox proportional hazards models (marginal structural Cox models for cumulative), adjusted for demographic and clinical characteristics. We compared the 75 th percentile of the viral load distribution with the 25th percentile using the hazard function from the model for all PWH with a VTE and those with a pulmonary embolism.
During a median of 4.8 years of follow-up, 424 PWH developed VTE. In adjusted analyses, higher cumulative viral load (75th percentile vs. 25th percentile), the strongest viral load predictor, was associated with a 1.45-fold higher risk of VTE [95% confidence interval (95% CI): 1.22-1.72]. Low CD4 + cell count less than 100 cells/μl was associated with higher VTE risk (hazard ratio: 4.03, 95% CI: 2.76-5.89) as compared to at least 500 cells/μl. Findings were similar for PWH who had a pulmonary embolism ( n = 189).
Reducing HIV viral load and maintaining CD4 + cell count may help mitigate VTE risk in PWH.
艾滋病毒感染者(PWH)从抗逆转录病毒治疗中受益匪浅,但面临与年龄相关的合并症带来的额外挑战,尤其是包括静脉血栓栓塞(VTE)在内的心血管疾病。关于艾滋病毒血症和免疫缺陷对该人群VTE风险的影响知之甚少。
我们评估了2009年1月至2019年12月期间,综合临床系统艾滋病研究网络(CNICS)队列中21507名接受治疗的PWH发生的、经中心判定的VTE事件。我们研究了三种艾滋病毒载量指标(基线、当前、累积)和当前CD4 +细胞计数与VTE的关联。累积病毒载量(病毒血症的拷贝天数)使用梯形法则通过时间加权总和进行估算。我们使用Cox比例风险模型(累积的边际结构Cox模型)对病毒载量与VTE之间的关联进行建模,并对人口统计学和临床特征进行了调整。我们使用该模型的风险函数,将所有发生VTE的PWH以及发生肺栓塞的PWH的病毒载量分布的第75百分位数与第25百分位数进行了比较。
在中位4.8年的随访期间,424名PWH发生了VTE。在调整分析中,累积病毒载量较高(第75百分位数与第25百分位数相比),这是最强的病毒载量预测指标,与VTE风险高出1.45倍相关[95%置信区间(95%CI):1.22-1.72]。与至少500个细胞/μl相比,CD4 +细胞计数低于100个细胞/μl与更高的VTE风险相关(风险比:4.03,95%CI:2.76-5.89)。对于发生肺栓塞的PWH(n = 189),结果相似。
降低艾滋病毒载量并维持CD4 +细胞计数可能有助于降低PWH的VTE风险。